The efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia / 소아과
Korean Journal of Pediatrics
;
: 347-353, 2015.
Article
in English
| WPRIM
| ID: wpr-42543
ABSTRACT
PURPOSE:
The purpose of this study was to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonarydysplasia (BPD).METHODS:
The Interventional study was designed as a multicenter, prospective, and randomized trial, with open labeled and parallel-experimental groups, 66 infants were enrolled and allocated to either the case group (n=30) or the control group (n=36) based on gestational age (GA). Infants in the case group were given Montelukast sodium (Singulair) based on their body weight (BW). Zero week was defined as the start time of the study.RESULTS:
The incidence of moderate to severe BPD was not different between the groups (case group 13 of 30 [43.3%] vs. control group 19 of 36 [52.8%], P=0.912). Additionally, secondary outcomes such as ventilation index, mean airway pressure and resort to systemic steroids were not significantly different. There were no serious adverse drug reactions in either group, and furthermore the rate of occurrence of mild drug related-events were not significantly different (case group 10 of 42 [23.8%] vs. control group 6 of 48 (15.8%), P=0.414).CONCLUSION:
Montelukast was not effective in reducing moderate or severe BPD. There were no significant adverse drug events associated with Montelukast treatment.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Sodium
/
Steroids
/
Ventilation
/
Body Weight
/
Bronchopulmonary Dysplasia
/
Infant, Premature
/
Pharmacokinetics
/
Incidence
/
Prospective Studies
/
Gestational Age
Type of study:
Controlled clinical trial
/
Incidence study
/
Observational study
/
Prognostic study
Limits:
Humans
/
Infant
/
Infant, Newborn
Language:
English
Journal:
Korean Journal of Pediatrics
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS